SYDNEY, Nov. 20, 2026 (GLOBE NEWSWIRE) — Moomoo Australia and New Zealand today announced its largest local brand investment to date, signing on as platinum partner and official share-trading platform of the Sydney Roosters from the 2027 NRL season.

The deal coincides with the opening of Moomoo’s second retail store, in Melbourne’s eastern hub of Box Hill, marking one year since the brokerage opened its first physical site in Chatswood, Sydney.

Together, the moves cap four years of rapid local growth, signalling a broader push into mainstream retail and high-net-worth investing. Named Australia’s most-trusted investing app in Finder’s 2026 customer satisfaction awards, moomoo has also held the top spot as the nation’s most-downloaded share-trading app for two consecutive years.*

VictorRadley_MichaelMcCarthy

Sydney Roosters partnership

From the 2027 season, the moomoo logo will appear on the sternum of the Roosters’ NRL jersey and the front of their playing shorts, supported by match-day and community activations across Sydney.

“Partnering with a club of the Sydney Roosters’ calibre reflects our long-term commitment to the Australian market,” said Moomoo Australia and New Zealand chief executive officer Michael McCarthy. “Combining tier-one sporting visibility with face-to-face support in our stores helps build the familiarity and trust everyday Australians want before putting their money to work.”

Easts Group chief executive officer Joe Kelly welcomed the announcement. “We’re delighted to welcome moomoo to the Sydney Roosters as our platinum partner and official share-trading platform,” he said. “Moomoo is an ambitious, forward-thinking brand with a clear vision for its future. We see a strong alignment between its ambitions and the Roosters’ commitment to performance.”

An expanding presence

Since launching locally in 2022, Moomoo Australia and New Zealand has steadily expanded its physical and market presence. Alongside the new Box Hill store and further outlets planned for 2027, the brokerage recently launched Moomoo Priority for high-net-worth users and hosted its inaugural Australian investor day in partnership with Nasdaq. Across Australia and New Zealand the firm’s local headcount will reach 70 staff by the end of 2026.

About moomoo

Moomoo Securities Australia Ltd, a Sydney-based, wholly owned subsidiary of Nasdaq-listed Futu Holdings Ltd, operates the moomoo platform across Australia and New Zealand. The moomoo app gives users access to more than 10,000 shares and exchange-traded funds across the Australian, US and Hong Kong sharemarkets, with US brokerage starting from US99¢ per trade, 24 hours every trading day. The platform pairs low-cost execution with real-time Level 2 US market data, advanced charting, an AI-powered assistant, curated financial news and user forums.

*Source: Sensor Tower, brokerage app downloads in Australia from January 1, 2025 to June 30, 2026. Combined total downloads for the moomoo app on Australian iOS and Android stores (referring to the moomoo global app from January 1, 2025 to November 7, 2025, and the Moomoo Australia app from November 7, 2025 onwards). Ranking may change over time.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e2a79f52-42cd-4240-872a-96c9f2a00871

CONTACT: Media Contact:
Carlee Snyder
pr@us.moomoo.com

FORT WORTH, Texas, Nov. 19, 2026 (GLOBE NEWSWIRE) — Yesway, Inc. (Nasdaq: YSWY) (“Yesway”) today announced the pricing of the underwritten secondary offering of 5,000,000 shares of Yesway’s Class A common stock by certain of its existing stockholders at a price to the public of $19.00 per share. In addition, the underwriters of the offering have a 30-day option to purchase from the selling stockholders up to 750,000 additional shares of Class A common stock at the public offering price, less underwriting discounts and commissions. The selling stockholders will receive all of the net proceeds from this offering. The offering is expected to close on November 23, 2026, subject to customary closing conditions.

Morgan Stanley is acting as lead bookrunning manager for the offering. J.P. Morgan and Goldman Sachs & Co. LLC are acting as active bookrunning managers. Barclays, BMO Capital Markets, KeyBanc Capital Markets, Guggenheim Securities, Raymond James, and William Blair are also acting as bookrunners.

A registration statement relating to this offering was declared effective by the Securities and Exchange Commission on November 19, 2026. The offering is made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained for free by visiting EDGAR on the Securities and Exchange Commission’s (the “SEC”) website at www.sec.gov. Alternatively, copies of the final prospectus relating to the offering may be obtained from:

  • Morgan Stanley & Co. LLC
    Attention: Prospectus Department
    180 Varick Street, Second Floor
    New York, New York 10014
  • J.P. Morgan Securities LLC
    c/o Broadridge Financial Solutions
    1155 Long Island Avenue
    Edgewood, New York 11717
    Email: prospectus-eq_fi@jpmchase.com or postsalemanualrequests@broadridge.com
  • Goldman Sachs & Co. LLC
    Attention: Prospectus Department
    200 West Street
    New York, New York 10282
    Telephone: 1-866-471-2526
    Email: prospectus-ny@ny.email.gs.com

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Yesway

Established in 2015 and headquartered in Fort Worth, Texas, Yesway is an award-winning convenience store operator with approximately 420 stores across eight states in the Midwest and Southwest. Yesway is renowned for its iconic food service offerings, diverse grocery selections, and private-label products, including the famous Allsup’s deep-fried burrito. Through strategic acquisitions, the development and opening of more than 90 stores over the past several years, and a steadfast commitment to customer satisfaction and community engagement, Yesway continues to cement its position as one of the leading convenience retailers in the United States.

Cautionary Note Regarding Forward-looking Statements

Certain statements made in this release that are not historical facts are “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the timing and completion of this offering, the satisfaction of customary closing conditions related to this offering, and any exercise of the underwriters’ option to purchase additional shares of Class A common stock from the selling stockholders. Statements based on historical data are not intended and should not be understood to indicate Yesway’s expectations regarding future events. Forward-looking statements provide current expectations or forecasts of future events or determinations. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Yesway’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Factors that could influence the realization of forward-looking statements include the risk factors outlined in the “Risk Factors” section of the preliminary prospectus related to the proposed offering and other filings Yesway may make from time to time with the SEC. Yesway does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact

Edelman Smithfield
IR@yesway.com

Media Contact

Erin Vadala
evadala@boltpr.com

SUDBURY, Ontario, Nov. 19, 2026 (GLOBE NEWSWIRE) — Magna Mining Inc. (TSXV: NICU) (OTCQX: MGMNF) (FSE: 8YD) (“Magna” or the “Company”) is pleased to announce that further to its news release dated October 8, 2026 titled “Magna Mining Reports Results of Levack Mine Preliminary Economic Assessment and Approves Restart of Production” the Company has filed on SEDAR+ an independent technical report titled “Levack Mine Preliminary Economic Assessment”.

The technical report was prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects. There are no material differences in the Report from the results disclosed in the Company’s news release dated October 7, 2026. A copy of the technical report is available under the Company’s profile on the SEDAR+ website at www.sedarplus.ca.

The independent technical report is dated November 18, 2026, with an effective date of September 30, 2026, and was prepared by AGP Mining Consultants Inc. with contributions from Orix Geoscience Inc., Qualitica Consulting Inc., Libertas Metallurgy Limited, MOS Mining Consultancy Pty Ltd., and Environmental Applications Group Inc., as well as input from Magna Mining Inc.

About Magna Mining Inc.

Magna Mining Inc. is a producing mining company with a strong portfolio of copper, nickel, and precious metals assets located in the world-class Sudbury mining district of Ontario, Canada. The Company’s McCreedy West Mine is currently in production, the adjacent Levack Mine is being restarted, and construction of the Crean Hill Project has been approved. These operations are supported by a pipeline of highly prospective past-producing properties including Podolsky, Kirkwood and Shakespeare.

Magna Mining is strategically positioned to unlock long-term shareholder value through continued production, exploration upside, and near-term development opportunities across its asset base.

Additional corporate and project information is available at www.magnamining.com and through the Company’s public filings on the SEDAR+ website at www.sedarplus.ca.

For further information, please contact:

Jason Jessup
Chief Executive Officer

or

Paul Fowler, CFA
Executive Vice President

705-482-9667
Email: info@magnamining.com

VANCOUVER, British Columbia, Nov. 19, 2026 (GLOBE NEWSWIRE) — Asante Gold Corporation (TSXV: ASE | GSE: ASG | OTCQX: ASGOF) (“Asante” or the “Company”) reminds investors that it will host an investor webinar tomorrow, Friday, November 20, 2026, at 8:00 a.m ET.

The webinar will be hosted by Campbell Baird, Acting Chief Executive Officer, Glenn Baldwin, Chief Development Officer, and Morgan Carroll, Incoming President and Chief Financial Officer, who will provide an update on the Company’s Bibiani and Chirano Gold Mines, followed by a live Q&A session.

Investors and other interested parties can register to attend the webinar through the following link: https://6ix.com/event/asante-gold-corporate-update-1. A recording of the webinar will be made available following the event.

The webinar presentation will be available on the Company’s website following the event at https://www.asantegold.com/presentation.

CONTACT INFORMATION

Frederick Attakumah, EVP and Country Director
Camilla Golding – Investor Relations Manager
investor@asantegold.com
+1 604 661 9400 or +233 303 972 147

ABOUT ASANTE GOLD CORPORATION

Asante Gold Corporation is a growing mid-tier gold producer, developer and explorer with a high-quality portfolio of assets located on two of West Africa’s most prolific and prospective gold belts in Ghana. The Company operates the Bibiani and Chirano Gold Mines on the Sefwi-Bibiani Gold Belt in Ghana’s Western North Region, where it holds an extensive and underexplored land position spanning more than 80 kilometres of strike. Asante is also advancing its Kubi Gold Project on the Ashanti Gold Belt, extending the Company’s footprint across Ghana’s most productive gold corridor. Committed to responsible mining and the creation of lasting value for its shareholders, people and host communities, Asante is listed on the TSX Venture Exchange, the Ghana Stock Exchange, and the OTCQX Market in the United States. Additional information is available on the Company’s website at www.asantegold.com.

About The Bibiani Gold Mine

Bibiani is an operating open pit gold mine situated in the Western North Region of Ghana, with historical gold production of more than 5 million ounces. The mine is fully permitted with mining and processing infrastructure on-site, including a refurbished process plant and associated mining infrastructure. Asante commenced mining at Bibiani in late February 2022, with commercial production announced on November 10, 2022.

About The Chirano Gold Mine

Chirano is an operating open pit and underground mine located in the Western Region of Ghana. The mine was first explored and developed in 1996 and began production in October 2005. Chirano comprises multiple open pit and underground operations and has produced over 3 million ounces of gold. Asante acquired the Chirano operation in August 2022.

Cautionary Statement of Forward-Looking Statements

Certain statements in this news release constitute forward-looking statements or forward-looking information. All statements, other than statements of historical fact, are forward-looking statements or information. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. The reader is referred to the risk factors identified in the Company’s management’s discussions and analysis and the most recent annual information form and the Company’s public disclosure record which is available on SEDAR+ (www.sedarplus.ca). Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except as required by securities laws and the policies of the securities exchanges on which the Company is listed, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

LEI Number: 529900F9PV1G9S5YD446. Neither CIRO nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Class A Ordinary Shares Expected to Begin Trading on a Split-Adjusted Basis on November 24, 2026

NEW YORK, NY , Nov. 19, 2026 (GLOBE NEWSWIRE) — Guardforce AI Co., Limited (“Guardforce AI” or the “Company”) (NASDAQ: GFAI), a technology-enabled service company providing solutions in Agentic AI, smart solutions in automation, robotics, and secured logistics, today announced that, pursuant to the approval of its board of directors and the approval of its shareholders at the Company’s reconvened extraordinary general meeting held on Tuesday, November 3, 2026 at 11:00 a.m. (Hong Kong standard time) (November 2, 2026 at 10:00 p.m. Eastern Time), it is effecting a 1-for-40 share consolidation of its ordinary shares (the “Reverse Share Split”), together with a related capital reduction, share subdivision and re-designation of its share capital into Class A ordinary shares and Class B ordinary shares. The Reverse Share Split and the related capital reduction, share subdivision and re-designation of its share capital are subject to registration by the Registrar of Companies of the Cayman Islands. The Reverse Share Split and re-designation became effective on November 11, 2026, upon registration by the Registrar. The Company’s Class A ordinary shares are expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on November 24, 2026. The Class A ordinary shares will replace the existing ordinary shares and continue to trade under the symbol “GFAI” and will have a new CUSIP number G4236L146.

Reverse Share Split Details

Every forty (40) issued and unissued ordinary shares, par value US$0.12 each, will be consolidated into one (1) share, par value US$4.80 each. Immediately afterwards, the par value of each issued share will be reduced to US$0.001 through a capital reduction, and each authorized but unissued share of par value US$4.80 will be subdivided into 4,800 shares of par value US$0.001 each. The Company’s authorized share capital will remain US$36,000,000. The reduction in par value will create a distributable reserve that the Company may use for purposes permitted by law and its articles of association, including to offset accumulated losses.

The Reverse Share Split will reduce the number of issued and outstanding ordinary shares from approximately 31,958,004 to approximately 799,233, subject to adjustment for the rounding up of fractional entitlements described below.

Fractional Shares

No fractional shares will be issued in connection with the Reverse Share Split. Any registered shareholder who would otherwise be entitled to a fractional share will receive one additional whole share, rounded up to the nearest whole number. No cash will be paid in lieu of fractional shares. Shareholders who hold their shares through a broker, bank or other nominee should contact that nominee, as the treatment of fractional entitlements in their accounts is subject to the nominee’s procedures.

Warrants and Other Securities

Proportionate adjustments will be made to the number of shares issuable and the exercise price under the Company’s outstanding warrants, options and other convertible securities in accordance with their terms. Following the Reverse Share Split, each outstanding PIPE warrant will be exercisable for 1/160 of one ordinary share, and the exercise price will be adjusted to US$186 per post-consolidation share.

Re-designation into Class A and Class B Ordinary Shares

Immediately following the Reverse Share Split, the Company’s issued and outstanding shares will be re-designated on a one-for-one basis into approximately 719,199 Class A ordinary shares and approximately 80,034 Class B ordinary shares, each with a par value of US$0.001. The Company’s authorized share capital will be re-designated into 34,500,000,000 Class A ordinary shares, 500,000,000 Class B ordinary shares and 1,000,000,000 preferred shares, each with a par value of US$0.001. The Company’s shareholders also approved the adoption of the Second Amended and Restated Memorandum of Association and the Third Amended and Restated Articles of Association to reflect the new share structure.

Each Class A ordinary share carries one (1) vote and each Class B ordinary share carries twenty (20) votes on all matters submitted to a vote at general meetings of the Company. Class A and Class B ordinary shares vote together as a single class. Holders of Class B ordinary shares may convert them into Class A ordinary shares on a one-for-one basis at any time. Class B ordinary shares convert automatically upon transfer to any person that is not an affiliate of the holder or an existing holder of Class B ordinary shares. Class A ordinary shares are not convertible into Class B ordinary shares.

Immediately following the re-designation, all Class B ordinary shares will be held by Lei Wang, the Company’s Chairwoman and Chief Executive Officer. As a result, Ms. Wang’s voting power will increase from approximately 10% to approximately 69% of the total voting power of the Company’s outstanding shares.

Exchange Agent and Shareholder Actions

VStock Transfer, LLC is acting as exchange agent for the Reverse Share Split. Registered shareholders who hold their shares in book-entry form do not need to take any action; their accounts will be adjusted automatically. Shareholders who hold their shares through a broker, bank or other nominee will have their positions adjusted by that nominee. Holders of physical share certificates will receive instructions for exchanging their certificates from the exchange agent and should not submit certificates until requested to do so.

Equity Incentive Plan Amendment

Shareholders also approved Amendment No. 2 to the Guardforce AI Co., Limited 2022 Equity Incentive Plan, which increases the maximum number of shares available for grant from 15% of the issued and outstanding ordinary shares to 20% of the issued and outstanding Class A ordinary shares at the time of grant.

About Guardforce AI Co., Limited

Guardforce AI Co., Limited (NASDAQ: GFAI) is a technology-enabled service company built on real-world service operations, trusted client relationships, and commercial smart service solutions. With its legacy secured logistics business as the operating foundation, the Company is expanding its first commercial growth curve through Smart Solutions across retail, hospitality, security, and other service environments, while building AI-native services as its second strategic growth engine. For more information, visit www.guardforceai.com, or X (formerly Twitter): @Guardforceai.

Safe Harbor Statement

This press release contains statements that do not relate to historical facts but are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can generally (although not always) be identified by their use of terms and phrases such as anticipate, appear, believe, continue, could, estimate, expect, indicate, intend, may, plan, possible, predict, project, pursue, will, would and other similar terms and phrases, as well as the use of the future tense. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of the business of the Company, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control, including the risks described in our registration statements and Annual Report on Form 20-F filed on April 21, 2026 under the heading “Risk Factors” as filed with the Securities and Exchange Commission. Actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this press release speak only as of the date hereof. Unless otherwise required by law, we undertake no obligation to publicly update or revise these forward-looking statements, whether because of new information, future events or otherwise.

Guardforce AI Corporate Communications:
Hu Yu
Email: yu.hu@guardforceai.com

NEW YORK, Nov. 19, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received the Leadership & Enterprise Growth Award at the Deloitte Technology Fast 50 Australia Awards which recognizes Australia’s fastest-growing technology companies and the founders, innovators and leaders shaping the future of the sector.

The award recognizes Mesoblast’s successful evolution to a commercial-stage biotechnology company following its U.S. launch of Ryoncil® (remestemcel-L-rknd), the first mesenchymal stromal cell therapy approved by the U.S. Food and Drug Administration (FDA).1

“We are pleased to receive this award from Deloitte which recognizes Mesoblast’s leadership excellence across innovation and scalability in the healthcare industry,” said Mesoblast Chief Executive Dr. Silviu Itescu. “The successful launch of RYONCIL has established a strong commercial foundation for Mesoblast and has enabled patients to access a life changing product. We are focused on building on that foundation, progressing our broader portfolio and delivering sustainable growth and long-term value for our shareholders.”

About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast

References / Footnotes

  1. Please see the full Prescribing Information at www.ryoncil.com

Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:

Corporate Communications / Investors  
Paul Hughes  
T: +61 3 9639 6036  
   
Media – Global Media – Australia
Rubenstein BlueDot Media
Caroline Nelson Steve Dabkowski
T: +1 703 489 3037 T: +61 419 880 486
E:cnelson@rubenstein.com E:steve@bluedot.net.au

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW

CALGARY, Alberta, Nov. 19, 2026 (GLOBE NEWSWIRE) — High Arctic Energy Services Inc. (TSX: HWO) (the “Corporation” or “High Arctic”) is pleased to announce that, further to its press release dated November 13, 2026, it has commenced the sending of its management information circular (the “Circular“) and related documents for the special meeting of High Arctic shareholders (the “Meeting“) in connection with the previously announced plan of arrangement (the “Arrangement“) under section 193 of the Business Corporations Act (Alberta) involving the Corporation and Newport Capital Ltd. (“Newport”) pursuant to which Newport, directly or through a wholly-owned subsidiary, has agreed to acquire all of the issued and outstanding common shares of High Arctic (the “High Arctic Shares”) for cash consideration of $1.59 per High Arctic Share, subject to adjustment in accordance with the terms of the Arrangement Agreement (the “Transaction”).

Meeting Details

The Meeting will be held on December 16, 2026 at 10:00 a.m. (Calgary Time) at the McMurray Room, Calgary Petroleum Club, 319 5 Avenue SW, Calgary, AB T2P 0L5. Shareholders are encouraged to vote well in advance of the meeting, in accordance with the instructions accompanying the form of proxy or voting instruction form mailed to shareholders.

If you have any questions about the information contained in the Notice of Meeting or the Circular, or require assistance with the procedure for voting, including to complete the accompanying form of proxy or letter of transmittal, please contact Odyssey Trust Company, by calling toll-free in Canada and the U.S. (toll free) 1-888-290-1175 or outside of Canada or the U.S. 1-587-885-0960 or by sending an email to shareholders@odysseytrust.com.

Other Matters to be Approved at the Meeting

At the Meeting, provided that the Arrangement is approved by the High Arctic shareholders, the shareholders will also be asked to approve as part of the Transaction, a cash distribution by way of a return of capital and/or a dividend (the “Shareholder Distribution”). The Shareholder Distribution expected to be paid to the High Arctic shareholders is expected to range from a minimum of $0.20 to a maximum of $0.30 per High Arctic Share.

In addition, the shareholders will be asked to approve an ordinary resolution (the “Option Payout Resolution”) approving the accelerated vesting, surrender and payout of all outstanding stock options of High Arctic (the “Options”), whether vested or unvested, effective as of the business day prior to the effective date of the Arrangement. Under the Option Payout Resolution, each holder of Options will receive a cash payment equal to the amount, if any, by which $1.59 plus the per share amount of the Shareholder Distribution exceeds the exercise price of each Option, less applicable withholdings.

Receipt of Interim Order

The Company is also announcing that on November 17, 2026, it was granted an interim order (the “Interim Order“) by the Court of King’s Bench of Alberta. The Interim Order authorizes High Arctic to proceed with various matters, including the holding of the Meeting to consider the vote on the Arrangement Resolution.

Further Information

Further details regarding the Arrangement can be found in the Arrangement Agreement, the Circular, Letter of Transmittal and the other Transaction documents which have filed on High Arctic’s SEDAR+ profile and are available for viewing at www.sedarplus.ca as well as on High Arctic’s website at 2026 Special Meeting – High Arctic Energy Services.

About High Arctic Energy Services

High Arctic is an energy services provider. High Arctic provides pressure control equipment and equipment supporting the high-pressure stimulation of oil and gas wells and other oilfield equipment ‎on a rental basis to exploration and production companies, from its bases in Whitecourt and Red Deer, Alberta‎. Additionally, High Arctic maintains a minority equity interest in Team Snubbing, a leading provider of well-control services to the oil and gas drilling industry with operations in Western Canada and Alaska, US. The High Arctic Shares trade on the TSX under the symbol “HWO”.

Currency

All amounts in this Press Release are denominated in Canadian dollars, unless otherwise indicated.

Forward-Looking Statements

This Press Release contains forward-looking statements. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “seek”, “propose”, “estimate”, “expect”, and similar expressions are intended to identify forward-looking statements. Such statements reflect the Corporation’s current views with respect to future events and are subject to certain risks, uncertainties, and assumptions. Many factors could cause the Corporation’s actual results, performance, or achievements to vary from those described in this Press Release. Should one or more of these risks or uncertainties materialize, or should assumptions underlying forward-looking statements prove incorrect, actual results may vary materially from those described in this Press Release as intended, planned, anticipated, believed, estimated or expected.

Specific forward-looking statements in this Press Release include, among others, statements pertaining to the following: the Transaction and the anticipated benefits thereof to High Arctic Shareholders; the consideration payable under the Transaction and any adjustments thereto; the expected amount, timing and tax treatment of the Shareholder Distribution and Option Payout Resolution; the anticipated timing of the High Arctic Meeting and the mailing and contents of the Circular; and the receipt of required shareholder, court, stock exchange and other approvals.

With respect to forward-looking statements contained in this Press Release, the Corporation has made assumptions regarding, among other things: the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary shareholder, court, stock exchange and other approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the Transaction; Newport’s ability to fund the consideration payable under the Transaction; High Arctic’s working capital, cash, indebtedness and transaction costs at closing; the ability of High Arctic to complete the disposition of its owned real property and that no event, change or other circumstance will occur that could give rise to the termination of the Arrangement Agreement.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the risk that the Transaction may be varied, delayed or terminated, or may not be completed on the terms described herein or at all; the failure to obtain the required shareholder, court, stock exchange or other approvals, or to satisfy or waive the other conditions to completion of the Transaction, in a timely manner or at all; the risk that the consideration payable to High Arctic Shareholders may be reduced pursuant to the purchase price adjustment provisions of the Arrangement Agreement; the risk that the Shareholder Distribution may be less than anticipated or may not be paid; the possibility that a termination fee may become payable by High Arctic; the risk that the announcement or pendency of the Transaction may adversely affect High Arctic’s business, operations and relationships with customers, suppliers and employees; the restrictions on the conduct of High Arctic’s business prior to completion of the Transaction; economic and financial conditions, including volatility in commodity prices; volatility in interest and exchange rates and capital markets; the level of demand and financial performance of the energy industry; changes in customer demand; and developments and changes in laws and regulations, including in the energy industry.

The Corporation’s actual results could differ materially from those anticipated in these forward-looking statements as a result of the risk factors set forth above and elsewhere in this Press Release, along with the risk factors set out in the most recent Annual Information Form filed on SEDAR+ at www.sedarplus.ca and the Circular. The forward-looking statements contained in this Press Release are expressly qualified in their entirety by this cautionary statement. These statements are given only as of the date of this Press Release. The Corporation does not assume any obligation to update these forward-looking statements to reflect new information, subsequent events or otherwise, except as required by law.

For further information contact:

Lonn Bate
Interim Chief Executive Officer   
P: 587-318-2218
P: +1 (800) 688 7143 

High Arctic Energy Services Inc.
Suite 2350, 330 – 5th Ave SW
Calgary, Alberta, Canada T2P 0L4
website: www.haes.ca
Email: info@haes.ca

WYOMISSING, Pa., Nov. 19, 2026 (GLOBE NEWSWIRE) — Gaming and Leisure Properties, Inc. (“GLPI”) (NASDAQ: GLPI) today announced the pricing of a public offering of $600,000,000 aggregate principal amount of senior notes due 2031 (the “Notes”), to be issued by its operating partnership, GLP Capital, L.P. (the “Operating Partnership”), and GLP Financing II, Inc., a wholly-owned subsidiary of the Operating Partnership (together with the Operating Partnership, the “Issuers”). The Notes priced at 99.486% of par value, with a coupon of 6.250%, and will mature on December 15, 2031. The Notes will be senior unsecured obligations of the Issuers, guaranteed by GLPI.

The Issuers intend to use the net proceeds from the offering for working capital and general corporate purposes, which may include funding of GLPI’s existing and new development commitments, acquisitions, development and expansion of projects at existing and new properties, repayment of indebtedness, capital expenditures and other general business purposes. The offering is expected to close on December 1, 2026, subject to the satisfaction of certain closing conditions.

The offering will be made under an effective shelf registration statement filed with the Securities and Exchange Commission (the “SEC”) and only by means of a prospectus and prospectus supplement. The preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available by visiting the EDGAR database on the SEC’s website at www.sec.gov.

Wells Fargo Securities, LLC, Citizens JMP Securities, LLC, Fifth Third Securities, Inc., Truist Securities, Inc., M&T Securities, Inc., Mizuho Securities USA LLC, SMBC Nikko Securities America, Inc., U.S. Bancorp Investments, Inc., BofA Securities, Inc., J.P. Morgan Securities LLC, RBC Capital Markets, LLC, KeyBanc Capital Markets Inc., Barclays Capital Inc., Capital One Securities, Inc., Scotia Capital (USA) Inc., Morgan Stanley & Co. LLC, Raymond James & Associates, Inc., Goldman Sachs & Co. LLC and Citigroup Global Markets Inc. are serving as joint book-running managers for the offering and TCBI Securities, Inc., doing business as Texas Capital Securities and Flagstar Securities, Inc. are serving as co-managers for the offering. A copy of the preliminary prospectus supplement, final prospectus supplement (when available) and the accompanying prospectus relating to the offering of the Notes may be obtained by calling Wells Fargo Securities, LLC at 1-800-645-3751, Citizens JMP Securities, LLC at 1-617-725-5500, Fifth Third Securities, Inc. at 1-866-531-5353, or Truist Securities, Inc. at 1-800-685-4786.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offer or sale will be made only by means of the prospectus supplement and prospectus forming part of the effective registration statement relating to these securities.

About Gaming and Leisure Properties

GLPI is engaged in the business of acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements, pursuant to which the tenant is responsible for all facility maintenance, insurance required in connection with the leased properties and the business conducted on the leased properties, including coverage of the landlord’s interests, taxes levied on or with respect to the leased properties and all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties. GLPI also extends loans that produce fixed or variable returns which may convert into leased rent upon project completion or stabilization.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including GLPI’s expectations regarding its ability to complete the offering and apply the net proceeds as indicated. Forward-looking statements can be identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” “may increase,” “may fluctuate,” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” or the negative or other variation of these or similar words, or by discussions of future events, strategies or risks and uncertainties. Such forward looking statements are inherently subject to risks, uncertainties and assumptions about GLPI and its subsidiaries, including risks related to the following: GLPI’s ability to successfully consummate the offering and apply the net proceeds as indicated; the ability of GLPI or its partners to successfully complete construction of various casino projects currently under development for which GLPI has agreed to provide construction development funding, including the Bally’s Chicago Casino Resort, and the ability and willingness of GLPI’s partners to meet and/or perform their respective obligations under the applicable construction financing and/or development documents; the impact that higher inflation rates and interest rates and uncertainty with respect to the future state of the economy could have on discretionary consumer spending, including the casino operations of GLPI’s tenants; unforeseen consequences related to United States (“U.S.”) government economic, monetary or trade policies and stimulus packages on inflation rates, interest rates and economic growth; geopolitical events, including recent conflicts in the Middle East, and their potential impact on U.S. Treasury yields and inflation rates; the ability of GLPI’s tenants to maintain the financial strength and liquidity necessary to satisfy their respective obligations and liabilities to third parties, including, without limitation, to satisfy obligations under their existing credit facilities and other indebtedness; the availability of and the ability to identify suitable and attractive acquisition and development opportunities and the ability to acquire and lease the respective properties on favorable terms; the degree and nature of GLPI’s competition; the ability to receive, or delays in obtaining, the regulatory approvals required to own and/or operate GLPI’s properties, or other delays or impediments to completing its planned acquisitions or projects; the potential of a new pandemic or similar national health crisis, including its effect on the ability or desire of people to gather in large groups (including in casinos), which could impact GLPI’s financial results, operations, outlooks, plans, goals, growth, cash flows, liquidity, and stock price; GLPI’s ability to maintain its status as a real estate investment trust (“REIT”), given the highly technical and complex Internal Revenue Code provisions for which only limited judicial and administrative authorities exist, where even a technical or inadvertent violation could jeopardize REIT qualification and where requirements may depend in part on the actions of third parties over which GLPI has no control or only limited influence; the satisfaction of certain asset, income, organizational, distribution, shareholder ownership and other requirements on a continuing basis in order for GLPI to maintain its REIT status; the ability and willingness of GLPI’s tenants and other third parties to meet and/or perform their obligations under their respective contractual arrangements with GLPI, including lease and note requirements and in some cases, their obligations to indemnify, defend and hold GLPI harmless from and against various claims, litigation and liabilities; the ability of GLPI’s tenants to comply with laws, rules and regulations in the operation of its properties, to deliver high quality services, to attract and retain qualified personnel and to attract customers; the ability to generate sufficient cash flows to service and comply with financial covenants under GLPI’s outstanding indebtedness; GLPI’s ability to access capital through debt and equity markets in amounts and at rates and costs acceptable to GLPI, including for the satisfaction of GLPI’s funding commitments to the extent drawn by its partners, acquisitions or refinancings due to maturities; the ability of GLPI’s tenants to decline GLPI’s funding commitments by seeking alternative financing solutions and/or if GLPI’s tenants do elect to utilize GLPI’s funding commitments, the amounts drawn and the timing of these draws may be different than what GLPI assumed; adverse changes in GLPI’s credit rating; the availability of qualified personnel and GLPI’s ability to retain its key management personnel; changes in the U.S. tax law and other federal, state or local laws or regulations, whether or not specific to real estate, REITs or the gaming, lodging or hospitality industries; changes in accounting standards; the impact of weather or climate events or conditions, natural disasters, acts of terrorism and other international hostilities, war (including the current conflict between Russia and Ukraine and conflicts in the Middle East) or political instability; the risk that the historical financial statements do not reflect what the business, financial position or results of operations of GLPI may be in the future; other risks inherent in the real estate business, including potential liability relating to environmental matters and illiquidity of real estate investments; and other factors described in GLPI’s Annual Report on Form 10-K for the year ended December 31, 2025, as may be supplemented by Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, each as filed with the SEC. GLPI undertakes no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this press release may not occur as presented or at all.

Contact
Gaming and Leisure Properties, Inc.
Carlo Santarelli
SVP Corporate Strategy & Investor Relations
610/378-8232
investorinquiries@glpropinc.com

Investor Relations
Joseph Jaffoni at JCIR
212/835-8500
glpi@jcir.com

  • With additional patients and longer follow-up, the combination of RASONQUE plus gemcitabine and nab-paclitaxel demonstrated deep and durable responses in the first-line treatment setting
  • Results support the ongoing Phase 3 RASolute 303 trial in patients with treatment-naïve metastatic pancreatic cancer

REDWOOD CITY, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced encouraging updated results from the Phase 1/2 RMC-GI-102 open-label study evaluating RASONQUE (daraxonrasib) in combination with gemcitabine and nab-paclitaxel (GnP) as a potential first-line treatment for patients with metastatic pancreatic adenocarcinoma (PDAC). The data will be presented today during a late-breaking oral session at the EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

As of September 28, 2026, 61 patients in the first-line metastatic PDAC cohort of the Phase 1/2 RMC-GI-102 open-label study had received RASONQUE (200 mg) plus GnP, with median follow-up of 18.3 months. In the updated analysis, the confirmed objective response rate was 60.7% (95% confidence interval [CI]: 47.3–72.9), including complete responses in 8.2% of patients. The disease control rate was 90.2% (95% CI: 79.8–96.3) and median duration of response was 11.1 months (95% CI: 7.6- 18.4). Median progression free survival (PFS) was 12.8 months (95% CI: 10.8–18.4) and the twelve-month overall survival was 76.6% (95% CI: 63.7-85.4). The safety profile was consistent with the known safety profiles previously observed for both RASONQUE and GnP. This update builds on findings previously presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026.

“With longer follow-up and a larger patient population, we are seeing a notable combination of high response rates, including deep complete responses, and durable disease control, with median progression-free survival exceeding one year,” said Wungki Park, M.D., M.S., medical oncologist at the David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, RMC-GI-102 and RASolute 303 investigator, and presenter of the data at ENA. “The emerging survival signal is meaningful and is estimated at 76.6% for patients to be alive at one year. Taken together, these findings provide a compelling rationale to further evaluate daraxonrasib as a potential first-line treatment option.”

“People with treatment-naïve metastatic pancreatic cancer urgently need more effective treatment options, given the limited clinical benefit of current chemotherapy regimens,” said Alan Sandler, M.D., chief development officer of Revolution Medicines. “The FDA’s recent Breakthrough Therapy Designation for RASONQUE plus GnP in this setting underscores the urgency of this work. The durability of treatment shown with these updated Phase 1/2 results is particularly encouraging and supports the ongoing Phase 3 RASolute 303 trial, which is evaluating RASONQUE both as a monotherapy and in combination with GnP versus GnP alone in patients with treatment-naïve metastatic PDAC, independent of tumor RAS genotype.”

The presentation (8LBA), titled “Daraxonrasib plus Gemcitabine/Nab-Paclitaxel (GnP) as First-Line (1L) Treatment for Patients (Pts) with Metastatic Pancreatic Adenocarcinoma (mPDAC),” will be delivered by Dr. Park during a late-breaking oral session on November 20, 2026, at the ENA Symposium in Barcelona, Spain.

About Pancreatic Adenocarcinoma (PDAC)
Pancreatic adenocarcinoma, or PDAC, is the most common form of pancreatic cancer and among the most challenging malignancies. RAS, a key growth control switch in human cells, is the main driver of pancreatic cancer, which is characterized by excessive RAS signaling. Each year, approximately 500,000 people globally are diagnosed with PDAC and it is the seventh leading cause of cancer-related deaths worldwide.1,2

Because early-stage pancreatic cancer often causes few or no symptoms, approximately 80% of patients are diagnosed after the disease has spread, when treatment options are more limited.3 For patients with metastatic PDAC, the five-year relative survival rate is approximately 3% worldwide.4

About RASONQUE® (daraxonrasib)
RASONQUE (daraxonrasib) is an oral, RAS(ON) multi-selective, noncovalent, tri-complex inhibitor (TCI), approved by the U.S. FDA for the treatment of adult patients with metastatic pancreatic adenocarcinoma (PDAC) who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.5 In the European Union, RASONQUE is approved by the European Commission for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. RASONQUE is being investigated through a global Phase 3 registrational program in patients with PDAC and metastatic RAS mutant non-small cell lung cancer (NSCLC). Outside the U.S. and the European Union, RASONQUE is an investigational agent that has not been approved by any regulatory authority.

U.S. FDA APPROVED INDICATION
RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

IMPORTANT SAFETY INFORMATION FOR U.S. APPROVED INDICATION
RASONQUE is associated with the following Warnings and Precautions: Dermatologic and Soft Tissue Toxicity, Stomatitis and Oral Disorders, Diarrhea, Gastrointestinal Perforation, Interstitial Lung Disease (ILD)/Pneumonitis, and Embryo-Fetal Toxicity.

WARNINGS AND PRECAUTIONS

Dermatologic and Soft Tissue Toxicity
RASONQUE can cause dermatologic toxicity, which may be severe. Clinical manifestations included, but were not limited to, rash, pruritus, paronychia, dry skin, and skin fissures. In clinical trials of patients with pancreatic adenocarcinoma, dermatologic toxicity occurred in 86% of patients treated with RASONQUE, of which 10% were Grade 3.

Monitor patients who develop dermatologic or soft tissue toxicities while receiving RASONQUE. Initiate prophylactic measures (e.g., topical corticosteroids, emollient creams, sunscreen, oral antibiotics) prior to the first dose of RASONQUE to reduce the risk of moderate to severe dermatologic reactions. Advise patients to limit sun exposure while taking RASONQUE. Initiate supportive measures (e.g., oral corticosteroids) as clinically indicated, and consider dermatologic consultation. Withhold, reduce the dose, or permanently discontinue RASONQUE based on severity.

Stomatitis and Oral Disorders
RASONQUE can cause stomatitis, including mouth ulcers and oral mucositis. In clinical trials of patients with pancreatic adenocarcinoma, stomatitis occurred in 57% of patients, of which 9% were Grade 3.

Monitor patients for signs and symptoms of stomatitis while receiving RASONQUE. Initiate a steroid-containing mouthwash for treatment of stomatitis and administer other topical treatments (e.g., chlorhexidine mouthwash, 2% lidocaine viscous) as clinically indicated. Withhold, reduce the dose, or permanently discontinue RASONQUE based on severity.

Diarrhea
RASONQUE can cause diarrhea. In clinical trials of patients with pancreatic adenocarcinoma, diarrhea occurred in 63% of patients, of which 6% were Grade 3.
If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Withhold, reduce the dose, or permanently discontinue RASONQUE based on severity.

Gastrointestinal Perforation
RASONQUE can cause gastrointestinal perforation. In clinical trials of patients with pancreatic adenocarcinoma, gastrointestinal perforation occurred in 0.9% of patients treated with RASONQUE, of which 0.5% were Grade 3, one event was Grade 4, and one event was fatal.

Monitor patients for gastrointestinal perforation. Withhold RASONQUE if gastrointestinal perforation is suspected. Reduce the dose or permanently discontinue RASONQUE if no other potential causes of gastrointestinal perforation are identified.

Interstitial Lung Disease (ILD)/Pneumonitis
RASONQUE can cause interstitial lung disease or pneumonitis. In clinical trials of patients with pancreatic adenocarcinoma, ILD/pneumonitis occurred in 2.4% of patients treated with RASONQUE, of which 0.9% were Grade 3, and one event was fatal.

Monitor patients for new or worsening pulmonary symptoms. Withhold RASONQUE if ILD/pneumonitis is suspected. Reduce the dose or permanently discontinue RASONQUE if no other potential causes of ILD/pneumonitis are identified.

Embryo-Fetal Toxicity
Based on findings in animals, RASONQUE can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with RASONQUE and for 1 week after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with RASONQUE and for 1 week after the last dose.

ADVERSE REACTIONS
Serious adverse reactions occurred in 30% of patients treated with RASONQUE. Serious adverse reactions occurring in ≥ 2% of patients treated with RASONQUE were diarrhea (3.7%), pyrexia (3.3%), sepsis (2.9%), fatigue (2.1%), and hemorrhage (2.1%).

Adverse reactions leading to permanent discontinuation of RASONQUE occurred in 2.9% of patients, including two patients who discontinued due to rash (0.8%).

The most common (≥ 20%) adverse reactions in patients treated with RASONQUE were rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage.

DRUG INTERACTIONS

  • Strong CYP3A Inhibitors with P-gp Inhibition: Avoid concomitant use.
  • Strong CYP3A Inhibitors without P-gp Inhibition: Reduce RASONQUE dosage.
  • Moderate CYP3A Inhibitors with or without P-gp Inhibition: Reduce RASONQUE dosage.
  • P-gp Inhibitors: Reduce RASONQUE dosage.
  • Cyclosporine A: Avoid concomitant use.
  • Strong CYP3A Inducers: Avoid concomitant use. Increase RASONQUE dosage if concomitant use cannot be avoided.
  • Moderate CYP3A Inducers: Increase RASONQUE dosage.
  • P-gp Substrates: Take at least 4 hours apart from RASONQUE.

PROPHYLACTIC MEASURES
When initiating RASONQUE and throughout treatment, prophylactic and concomitant medications are recommended to reduce the risk of dermatologic reactions:

  • administer a topical corticosteroid (applied to the face and chest) and emollient creams;
  • advise patients to limit sun exposure and use broad-spectrum sunscreen (SPF 30 or higher); and
  • consider prophylactic oral antibiotics (e.g., doxycycline or minocycline).

Please see U.S. Full Prescribing Information for RASONQUE.

About Revolution Medicines, Inc.

Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. For more information, visit www.revmed.com and follow Revolution Medicines on LinkedIn, X (Twitter) and Instagram.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding the broad potential of RAS(ON) inhibition; the potential of RASONQUE in combination with GnP as a first-line treatment for patients with metastatic PDAC; treatment practices; the design, progress and expected outcomes of the company’s ongoing and planned clinical trials, including RASolute 303; the extent to which updated results from the Phase 1/2 RMC-GI-102 study may support or be predictive of results in the RASolute 303 trial or other clinical trials; the company’s regulatory interactions, plans and potential future regulatory submissions or approvals, including for RASONQUE in additional indications outside the U.S.; the potential for Breakthrough Therapy Designation to expedite the development and review of new medicines; the commercialization of RASONQUE; and progression of clinical studies and findings from these studies, including the tolerability, safety, and potential efficacy of the company’s product and product candidates being studied.

Forward-looking statements are typically, but not always, identified by the use of words such as “aims,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “up to,” “will,” “would,” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ development stages, the process of designing and conducting preclinical and clinical trials, risk that results from earlier or ongoing clinical trials, including updated or interim results from open-label studies with limited patient numbers, may not be predictive of future results or may change as more patient data become available or following more comprehensive review of the data, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 4, 2026, and its future periodic reports to be filed with the SEC. Any forward-looking statements in this press release speak only as of the date of this press release. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events.

Revolution Medicines Media & Investor Contacts

Media
media@revmed.com

Investors
investors@revmed.com

References

1 Park W, Chawla A, O’Reilly EM. Pancreatic cancer: A review. JAMA. 2021;326(9):851-862. doi:10.1001/jama.2021.13027
2 González-López J, Bauza ME, Pérez-Rojas J, et al. Pancreatic adenocarcinoma: Diagnosis by ultrasound-guided fine-needle aspiration—cyto-histological correlation and experience at a multidisciplinary tertiary reference center. Diagn Cytopathol. 2026;54(6):403-416. doi:10.1002/dc.70097
3 Rahib L, Coffin T, Kenner B. Factors driving pancreatic cancer survival rates. Pancreas. 2025;54(6):e530-e536. doi:10.1097/MPA.0000000000002489
4 Levine JM, Rompen IF, Franco JC, et al. The impact of metastatic sites on survival rates and predictors of extended survival in patients with metastatic pancreatic cancer. Pancreatology. 2024;24(6):887-893. doi:10.1016/j.pan.2024.06.004
5 RASONQUE (daraxonrasib) Prescribing Information. Redwood City, CA: Revolution Medicines, Inc.; August 2026.

VANCOUVER, British Columbia, Nov. 19, 2026 (GLOBE NEWSWIRE) — Highland Copper Company Inc. (TSXV: HI; OTCQB: HDRSF) (“Highland” or the “Company”) is pleased to announce its financial and operational results for the three months ended September 30, 2026.

The Company’s unaudited condensed interim consolidated financial statements and accompanying Management’s Discussion and Analysis (“MD&A”) for the period ended September 30, 2026 are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and on the Company’s website at https://www.highlandcopper.com/investors/#financial-reports.

Q1 2027 Financial Highlights

  • Cash Position: Ended the quarter with $16.6 million in cash, compared to $18.9 million as of June 30, 2026.
  • Working Capital: Maintained positive working capital of $15.2 million as of September 30, 2026.
  • Net Loss: Recorded a net loss of $2.1 million for the three months ended September 30, 2026 ($(0.00) per share) compared to net loss of $4.1 million during the comparative period last year ($(0.01) per share).

Selected Financial Results

The following table summarizes selected financial data for the three months ended September 30, 2026 and 2025:

Selected Financial Results

Q1 2027 Operational Highlights & Outlook

  • State Infrastructure Grant: The Company announced final approval by the Michigan Strategic Fund of $50 million in performance-based grant funding under the Strategic Site Readiness Program (“SSRP“) to support the development of the Company’s permitted Copperwood Project and related infrastructure improvements in Gogebic County, Michigan. The grant consists of:
    • US$45.0 million to Copperwood Resources Inc., a wholly owned subsidiary of Highland Copper, to support eligible infrastructure expenditures associated with the development of Copperwood; and
    • US$5.0 million to the Gogebic County Road Commission to support critical local infrastructure improvements associated with the Project and benefiting the broader region.
    • In addition to the SSRP funding, the Gogebic County Road Commission has secured a $7.5 million Transportation Economic Development Fund (“TEDF“) Category A grant from the Michigan Department of Transportation (“MDOT“).
    • Subsequent to quarter-end, Copperwood Resources Inc. concluded the formal grant agreement with the Michigan Strategic Fund. The grant is conditional upon the Company providing evidence, on or before March 31, 2028, that it has obtained commitments satisfactory to the MEDC for US$150,000,000 in additional project financing (the “Project Milestone”).  Once the Company demonstrates that it has met the Project Milestone, it will be eligible for reimbursement of expenditures made on or before March 31, 2033, on site preparation and improvement necessary to support the development of the Project. The grant is subject to certain completion milestones, including that the Company has established a minimum of 380 qualified jobs at the Project.
  • Wetland Delineation and Permitting: As disclosed in the Management’s Discussion and Analysis for the year ended June 30, 2026, the Company initiated a wetland delineation survey to inform whether a supplemental permit may be appropriate before construction. Given the passage of time since the original wetland delineation and permit, it was considered prudent to determine if new wetland had emerged that required permitting. Through this exercise, it was determined there is a modest amount of acreage that will require a supplemental Part 303 Wetland Protection permit. This is consistent with the assessment by Michigan’s Department of Environment, Great Lakes, and Energy. It is anticipated that the formal wetland delineation will conclude in Q2 2027 with a goal of receiving the permit by Q4 2027.
     
  • Environmental Stewardship and Site Work: Continued early site work and environmental mitigation activities, including stream and wetland mitigation, revegetation, corrective work, and ongoing monitoring and maintenance. The Company also completed an off-site bridge replacement on budget and on time as a stream mitigation project and is in process to establish a 717-acre wetland preservation area.
     
  • Integrated Mine Plan Review: Advanced the Integrated Mine Plan Review, including refinement of mine design criteria, mine design and production scheduling, geotechnical assumptions, infrastructure and equipment requirements, and operating cost estimates. The work is intended to optimize the Copperwood mine plan and establish an updated technical and cost basis for subsequent project engineering and the planned update to the Copperwood Feasibility Study.

Scientific and Technical Information

The scientific and technical information contained in this news release has been reviewed and approved by Trace Arlaud, a “Qualified Person” as defined under NI 43-101. Ms. Arlaud is a consultant to Highland Copper and serves as the Company’s Project Director.

About Highland Copper Company

Highland Copper Company Inc. is a Canadian company focused on exploring and developing copper project in the Upper Peninsula of Michigan, U.S.A. The Company has 739,158,985 common shares issued and outstanding. Its common shares are listed on the TSX Venture Exchange under the symbol “HI” and trade on the OTCQB Venture Market under symbol “HDRSF”.

More information about the Company is available on the Company’s website at www.highlandcopper.com and on SEDAR at www.sedar.com.

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of Canadian securities legislation and “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking statements”). These forward-looking statements are made as of the date of this news release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities legislation. Forward-looking statements relate to future events or future performance and reflect expectations or beliefs of the Company’s management regarding future events. Forward-looking statements in this news release include, without limitation, statements regarding: (i) satisfaction of the financing and other eligibility and performance conditions under the SSRP grant agreement, and the availability, amount and timing of reimbursements for eligible expenditures; (ii) the anticipated completion of wetland delineation and the targeted receipt of a supplemental Part 303 Wetland Protection permit; (iii) the establishment of the planned 717-acre wetland preservation area and related activities; and (iv) the intended outcomes of the Integrated Mine Plan Review, including optimization of the Copperwood mine plan and development of an updated technical and cost basis for subsequent project engineering and the planned update to the Copperwood Feasibility Study.  In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes” or variations of such words and phrases, or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. The absence of these words does not mean that a statement is not forward-looking.

By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, but are not limited to: (i) the Company’s ability to raise capital necessary to advance the Copperwood Project; (ii) risks related to the volatility in future prices of copper and other metals which may have a negative impact on the Company’s share price or ability to raise capital; (iii) the accuracy of mineral resource and mineral reserve estimates, and any inaccuracy of the assumptions used in preparing the Copperwood Feasibility Study; (iv) increased operating and capital costs which could negatively impact not only the Company’s operations, but also the results of the Copperwood Feasibility Study; (v) the impact of inflation on project costs and current and future project budgets; (vi) changes to governmental regulations, compliance with governmental regulations and environmental laws and regulations; (vii) reliance on approvals and permits from governmental authorities and the ability of the Company to maintain existing permits and obtain additional permits or permit amendments required for Copperwood; (viii) challenges to title to the Company’s mineral properties; (ix) the ability of the Company to maintain its social license to operate; (x) changes in international trade and other relations or increased protectionist policies may affect costs generally, and the Company’s ability to operate in a foreign jurisdiction; (xi) dependence on key management personnel; (xii) competition in the mining industry; (xiii) the inability of the Company to insure against all risks; (xiv) unavailability of skilled labour, contractors, equipment, power or other infrastructure on acceptable terms or within anticipated timeframes; (xv) failure to satisfy grant eligibility or performance conditions, delayed or reduced reimbursements, and changes to or withdrawal of government funding or financing programs; (xvi) cybersecurity incidents, including cyberattacks, ransomware, phishing, fraud, unauthorized access and data breaches affecting the Company or its service providers, which could result in loss of funds or data, disruption of activities, delays to project development, additional costs, liability or reputational harm; and (xvii) inherent risks involved in the exploration, development and production of minerals, and the presence of unknown geological and other physical and environmental hazards at the Company’s projects, as well as those factors detailed from time to time in the Company’s interim and annual financial statements and MD&A, including the “Risks and Uncertainties” sections of the Company’s MD&A for the year ended June 30, 2026, the Copperwood Feasibility Study, and the Company’s annual information form (if applicable) all of which are, or will be, filed and available for review  under the Company’s profile on SEDAR+ at www.sedarplus.ca. Although the Company has attempted to identify important factors that could cause actual results, performance, or achievements to differ materially from those described in these forward-looking statements, there may be other factors that cause results, performance, or achievements not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on these forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information or media requests, please contact:

Barry O’Shea, CEO
Email: info@highlandcopper.com 
Phone: +1-450-677-2455
Website: www.highlandcopper.com 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6a33a1e5-d6cf-4469-b0a7-ae88397cab7d

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.